Captor Therapeutics Announces Molecular Targets for CT-01 Program Developing PDT Therapy for Hepatocellular Carcinoma
- CT-01 compounds induce degradation of GSPT1, SALL4 and another yet undisclosed neo-substrate
- The unique degradation profile supports the strong competitive potential of the program
- Generation of compelling preclinical data demonstrating HCC tumor regression
- CT-01 on track to enter clinical development in 2023
WROCLAW, Poland, April 12, 2022 (GLOBE NEWSWIRE) — Captor Therapeutics SA (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces molecular targets for one of its major pipeline projects. designated CT-01, which focuses on the development of PDT therapy for hepatocellular carcinoma (HCC).
Irresistible in vitro and in vivo preclinical data demonstrate that candidate compounds CT-01 induce degradation of the GTP-binding subunit of eukaryotic peptide chain releasing factor ERF3A (GSPT1), Sal-like protein 4 (SALL4) and a another undisclosed neo-substrate having an essential function in tumorigenesis. GSPT1 is a protein involved in translation termination, a process in which ribosomes synthesize proteins after transcription of DNA into RNA. There is a demonstrated link between GSPT1 degradation and antitumor activity. SALL4 is a transcription factor expressed in human fetal liver and silenced in adults but often re-expressed in patients with HCC, which correlates with poor prognosis.
“CT-01 targets fundamentally contribute to the development of cancer and their removal has potent therapeutic potential in the treatment of hepatocellular carcinoma as well as several other malignancies,” said Dr. Tom Shepherd, chief executive of Captor Therapeutics. “We have previously reported compelling preclinical data showing that CT-01 candidate compounds induced strong tumor regression in a Hep 3B2.1-7 mouse model of human HCC. These compelling efficacy data, together with the unique degradation profile announced today, support our growing confidence in the strong scientific, medical and competitive value of the project.”
Captor Therapeutics plans to advance CT-01 to Investigative New Drug Application (IND) enabling studies and initiate clinical trials in 2023.
About the CT-01 and HCC project
The CT-01 project aims to develop, based on targeted protein degradation technology, a drug candidate that will halt the progression of hepatocellular carcinoma (HCC) and potentially offer significant benefits to patients. HCC, a form of liver cancer, is a significant unmet medical need because most patients are diagnosed at a late stage of the disease and current treatments provide limited benefits in terms of overall survival rates. With approximately 700,000 new cases each year, HCC is the second leading cause of cancer death. In patients diagnosed early, surgical removal of the tumor remains the only effective treatment. In unresectable HCC, the best result reported is the combination of Atezolizumab (Tecentriq®) plus Bevacizumab (Avastin®), where a median overall survival (OS) of 19.2 months and an overall response rate (ORR) of 29.8% were reported in the IMbrave150 study, indicating that there remains a considerable need for new treatments.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on harnessing targeted protein degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with unmet medical needs. PDT is a breakthrough approach to developing new drugs that can address novel molecular targets deemed “irreversible” with conventional drug development approaches, as well as provide additional treatment options for diseases where existing drugs cannot. not provide optimal medical benefit. Captor is currently developing therapies for serious under-treated conditions, including malignancies and autoimmune diseases.
More information about Captor Therapeutics is available at: http://www.captortherapeutics.com
For more information, please contact:
|Relations with Polish media and investors:
Point of view
+48 601 155 582
|Relations with international investors:
Guillaume van Renterghem
+41 (0)76 735 01 31